A Study to Determine the Bioequivalence of SCH 900068 Compared to Marketed Products (Protocol No. P07551)
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The intent of this study is to demonstrate that single doses of the Final Market Image (FMI)
ezetimibe/atorvastatin 10mg/10mg and 10mg/80mg fixed dose combination (FDC) tablets are
bioequivalent to the same doses of ezetimibe (ZETIA®) and atorvastatin (LIPITOR®) that are
coadministered as individual tablets in healthy adults.